Zentalis
PublicZentalis is now publicly traded
The data on this page reflects Zentalis's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Apr 2, 2020
Last Round
Follow-on Offering
Jun 15, 2023
Total Funding Raised
$1.19B
Company Overview
Zentalis Pharmaceuticals (NAS: ZNTL) is a biopharmaceutical company focused on discovering and developing small molecule therapeutics that target key biological pathways in cancer.
Sector
Healthcare
AI Layer
Non-AI
Keywords
Zentalis Comparables
Compare Zentalis with similar companies based on industry and business-model similarity.
No public comparables are available for Zentalis. Request access to learn about comparables coverage.
Request accessZentalis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Jun 15, 2023 | ||||
| Follow-on Offering | May 18, 2022 | ||||
| Private Placement | Apr 27, 2022 | ||||
| Follow-on Offering | Jul 1, 2021 | ||||
| Follow-on Offering | May 21, 2020 | ||||
IPO | Apr 2, 2020 |
Zentalis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Matrix | Series C |
| Redmile Group | Series C |
| Jefferies | Follow-on Offering, IPO |
| Surveyor Capital | Series C |
| Farallon Capital Management | Series C |
| Perceptive Advisors | Series A, Series B, Series C |
| Guggenheim Securities | Follow-on Offering, IPO |
Zentalis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access